Could the appropriate anti-diabetic therapy be mixed insulin in dialysis patients?

Background A good glycemic regulation should be provided to reduce mortality and morbidity in patients with end-stage renal failure due to diabetes mellitus. However, the use of insulin therapies in patients with renal failure is troublesome due to the increased rate of side effects. In our study, w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of diabetes in developing countries 2021-06, Vol.41 (2), p.288-292
Hauptverfasser: Demircan, Vehbi, Yıldırım, Yaşar, Aydın, Emre, Kara, Ali Veysel, Aydın, Fatma Yılmaz, Yılmaz, Zülfükar, Kadiroğlu, Ali Kemal, Tuzcu, Alpaslan Kemal, Pekkolay, Zafer
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 292
container_issue 2
container_start_page 288
container_title International journal of diabetes in developing countries
container_volume 41
creator Demircan, Vehbi
Yıldırım, Yaşar
Aydın, Emre
Kara, Ali Veysel
Aydın, Fatma Yılmaz
Yılmaz, Zülfükar
Kadiroğlu, Ali Kemal
Tuzcu, Alpaslan Kemal
Pekkolay, Zafer
description Background A good glycemic regulation should be provided to reduce mortality and morbidity in patients with end-stage renal failure due to diabetes mellitus. However, the use of insulin therapies in patients with renal failure is troublesome due to the increased rate of side effects. In our study, we investigated the frequency of hypoglycemia and its symptoms in patient groups receiving intensive and mixed insulin therapies. Materials and methods This prospective study included 89 hemodialysis patients with DM-related stage 5 chronic kidney disease who were followed up in a nephrology clinic of a university hospital between January 2013 and August 2015. Our study group was divided into two groups as those receiving intensive insulin therapy and mixed insulin therapy. Group 1 and group 2 consisted of 46 patients and 43 patients, respectively. Hypoglycemia (glucose < 70 mg/dl) was investigated in patients with HbA1c levels that decreased below 7% after treatment, and the symptoms were evaluated according to the hypoglycemic scale. The results between the groups were evaluated using chi-square and Student’s t test Results A total of 89 patients were included in the study. HbA1c was 6.83% in the group receiving intensive insulin therapy and 6.95% in the group receiving mixed insulin therapy ( p > 0.05). Hypoglycemia was detected in 27 patients (58.7%) in the intensive insulin therapy group and 14 patients (32.6%) in the mixed insulin therapy group. There was a significant level of hypoglycemia in the group receiving intensive insulin therapy ( p < 0.05). In our study, the group receiving intensive insulin therapy had higher frequency and severity of common hypoglycemia symptoms such as confusion, sweating, weakness, dysphasia, palpitations, blurred vision, and feeling hungry. Conclusion There was a higher frequency of hypoglycemia under intensive insulin therapy in patients undergoing dialysis due to chronic kidney failure, which suggests that mixed insulin therapy is the ideal treatment to avoid hypoglycemia in this group of patients.
doi_str_mv 10.1007/s13410-020-00892-7
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2535300986</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2535300986</sourcerecordid><originalsourceid>FETCH-LOGICAL-c270t-5267f83d99bbad6489e03c4676eb159115411b2bad9037d1ae0516d851178943</originalsourceid><addsrcrecordid>eNp9UE1LxDAQDaLg-vEHPBU8R2eSpklOIotfsCDI3kPaZjVLt61JCu6_N2sFbx6GNzDvvZl5hFwh3CCAvI3ISwQKLBcozag8IgvUWlGuODsmC9CSU645nJKzGLcAQrCKL8jbcpi6tkgfrrDjGIYxeJty3ydPW29rl3xzmAY77ovaFTv_5drC93HqfJ-xyKRuH30sRpu861O8uyAnG9tFd_mL52T9-LBePtPV69PL8n5FGyYh0bxfbhRvta5r21al0g54U1aycjUKjShKxJrlmQYuW7QOBFatEohS6ZKfk-vZNl_9ObmYzHaYQp83Gia44ABaVZnFZlYThhiD25j84c6GvUEwh-jMHJ3J0Zmf6IzMIj6LYib37y78Wf-j-gY7GHCA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2535300986</pqid></control><display><type>article</type><title>Could the appropriate anti-diabetic therapy be mixed insulin in dialysis patients?</title><source>Springer Nature - Complete Springer Journals</source><creator>Demircan, Vehbi ; Yıldırım, Yaşar ; Aydın, Emre ; Kara, Ali Veysel ; Aydın, Fatma Yılmaz ; Yılmaz, Zülfükar ; Kadiroğlu, Ali Kemal ; Tuzcu, Alpaslan Kemal ; Pekkolay, Zafer</creator><creatorcontrib>Demircan, Vehbi ; Yıldırım, Yaşar ; Aydın, Emre ; Kara, Ali Veysel ; Aydın, Fatma Yılmaz ; Yılmaz, Zülfükar ; Kadiroğlu, Ali Kemal ; Tuzcu, Alpaslan Kemal ; Pekkolay, Zafer</creatorcontrib><description>Background A good glycemic regulation should be provided to reduce mortality and morbidity in patients with end-stage renal failure due to diabetes mellitus. However, the use of insulin therapies in patients with renal failure is troublesome due to the increased rate of side effects. In our study, we investigated the frequency of hypoglycemia and its symptoms in patient groups receiving intensive and mixed insulin therapies. Materials and methods This prospective study included 89 hemodialysis patients with DM-related stage 5 chronic kidney disease who were followed up in a nephrology clinic of a university hospital between January 2013 and August 2015. Our study group was divided into two groups as those receiving intensive insulin therapy and mixed insulin therapy. Group 1 and group 2 consisted of 46 patients and 43 patients, respectively. Hypoglycemia (glucose &lt; 70 mg/dl) was investigated in patients with HbA1c levels that decreased below 7% after treatment, and the symptoms were evaluated according to the hypoglycemic scale. The results between the groups were evaluated using chi-square and Student’s t test Results A total of 89 patients were included in the study. HbA1c was 6.83% in the group receiving intensive insulin therapy and 6.95% in the group receiving mixed insulin therapy ( p &gt; 0.05). Hypoglycemia was detected in 27 patients (58.7%) in the intensive insulin therapy group and 14 patients (32.6%) in the mixed insulin therapy group. There was a significant level of hypoglycemia in the group receiving intensive insulin therapy ( p &lt; 0.05). In our study, the group receiving intensive insulin therapy had higher frequency and severity of common hypoglycemia symptoms such as confusion, sweating, weakness, dysphasia, palpitations, blurred vision, and feeling hungry. Conclusion There was a higher frequency of hypoglycemia under intensive insulin therapy in patients undergoing dialysis due to chronic kidney failure, which suggests that mixed insulin therapy is the ideal treatment to avoid hypoglycemia in this group of patients.</description><identifier>ISSN: 0973-3930</identifier><identifier>EISSN: 1998-3832</identifier><identifier>DOI: 10.1007/s13410-020-00892-7</identifier><language>eng</language><publisher>New Delhi: Springer India</publisher><subject>Antidiabetics ; Diabetes ; Diabetes mellitus ; End-stage renal disease ; Family Medicine ; General Practice ; Health Administration ; Hemodialysis ; Hypoglycemia ; Insulin ; Kidney diseases ; Medical treatment ; Medicine ; Medicine &amp; Public Health ; Morbidity ; Nephrology ; Original Article ; Patients ; Renal failure ; Sweating</subject><ispartof>International journal of diabetes in developing countries, 2021-06, Vol.41 (2), p.288-292</ispartof><rights>Research Society for Study of Diabetes in India 2020</rights><rights>Research Society for Study of Diabetes in India 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c270t-5267f83d99bbad6489e03c4676eb159115411b2bad9037d1ae0516d851178943</cites><orcidid>0000-0002-7251-046X ; 0000-0002-5323-2257 ; 0000-0002-0378-8687 ; 0000-0002-1814-9773 ; 0000-0001-5424-5714 ; 0000-0001-7657-3065 ; 0000-0002-8101-2497 ; 0000-0002-1331-2906 ; 0000-0002-7768-2455</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13410-020-00892-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13410-020-00892-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Demircan, Vehbi</creatorcontrib><creatorcontrib>Yıldırım, Yaşar</creatorcontrib><creatorcontrib>Aydın, Emre</creatorcontrib><creatorcontrib>Kara, Ali Veysel</creatorcontrib><creatorcontrib>Aydın, Fatma Yılmaz</creatorcontrib><creatorcontrib>Yılmaz, Zülfükar</creatorcontrib><creatorcontrib>Kadiroğlu, Ali Kemal</creatorcontrib><creatorcontrib>Tuzcu, Alpaslan Kemal</creatorcontrib><creatorcontrib>Pekkolay, Zafer</creatorcontrib><title>Could the appropriate anti-diabetic therapy be mixed insulin in dialysis patients?</title><title>International journal of diabetes in developing countries</title><addtitle>Int J Diabetes Dev Ctries</addtitle><description>Background A good glycemic regulation should be provided to reduce mortality and morbidity in patients with end-stage renal failure due to diabetes mellitus. However, the use of insulin therapies in patients with renal failure is troublesome due to the increased rate of side effects. In our study, we investigated the frequency of hypoglycemia and its symptoms in patient groups receiving intensive and mixed insulin therapies. Materials and methods This prospective study included 89 hemodialysis patients with DM-related stage 5 chronic kidney disease who were followed up in a nephrology clinic of a university hospital between January 2013 and August 2015. Our study group was divided into two groups as those receiving intensive insulin therapy and mixed insulin therapy. Group 1 and group 2 consisted of 46 patients and 43 patients, respectively. Hypoglycemia (glucose &lt; 70 mg/dl) was investigated in patients with HbA1c levels that decreased below 7% after treatment, and the symptoms were evaluated according to the hypoglycemic scale. The results between the groups were evaluated using chi-square and Student’s t test Results A total of 89 patients were included in the study. HbA1c was 6.83% in the group receiving intensive insulin therapy and 6.95% in the group receiving mixed insulin therapy ( p &gt; 0.05). Hypoglycemia was detected in 27 patients (58.7%) in the intensive insulin therapy group and 14 patients (32.6%) in the mixed insulin therapy group. There was a significant level of hypoglycemia in the group receiving intensive insulin therapy ( p &lt; 0.05). In our study, the group receiving intensive insulin therapy had higher frequency and severity of common hypoglycemia symptoms such as confusion, sweating, weakness, dysphasia, palpitations, blurred vision, and feeling hungry. Conclusion There was a higher frequency of hypoglycemia under intensive insulin therapy in patients undergoing dialysis due to chronic kidney failure, which suggests that mixed insulin therapy is the ideal treatment to avoid hypoglycemia in this group of patients.</description><subject>Antidiabetics</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>End-stage renal disease</subject><subject>Family Medicine</subject><subject>General Practice</subject><subject>Health Administration</subject><subject>Hemodialysis</subject><subject>Hypoglycemia</subject><subject>Insulin</subject><subject>Kidney diseases</subject><subject>Medical treatment</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Morbidity</subject><subject>Nephrology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Renal failure</subject><subject>Sweating</subject><issn>0973-3930</issn><issn>1998-3832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9UE1LxDAQDaLg-vEHPBU8R2eSpklOIotfsCDI3kPaZjVLt61JCu6_N2sFbx6GNzDvvZl5hFwh3CCAvI3ISwQKLBcozag8IgvUWlGuODsmC9CSU645nJKzGLcAQrCKL8jbcpi6tkgfrrDjGIYxeJty3ydPW29rl3xzmAY77ovaFTv_5drC93HqfJ-xyKRuH30sRpu861O8uyAnG9tFd_mL52T9-LBePtPV69PL8n5FGyYh0bxfbhRvta5r21al0g54U1aycjUKjShKxJrlmQYuW7QOBFatEohS6ZKfk-vZNl_9ObmYzHaYQp83Gia44ABaVZnFZlYThhiD25j84c6GvUEwh-jMHJ3J0Zmf6IzMIj6LYib37y78Wf-j-gY7GHCA</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Demircan, Vehbi</creator><creator>Yıldırım, Yaşar</creator><creator>Aydın, Emre</creator><creator>Kara, Ali Veysel</creator><creator>Aydın, Fatma Yılmaz</creator><creator>Yılmaz, Zülfükar</creator><creator>Kadiroğlu, Ali Kemal</creator><creator>Tuzcu, Alpaslan Kemal</creator><creator>Pekkolay, Zafer</creator><general>Springer India</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><orcidid>https://orcid.org/0000-0002-7251-046X</orcidid><orcidid>https://orcid.org/0000-0002-5323-2257</orcidid><orcidid>https://orcid.org/0000-0002-0378-8687</orcidid><orcidid>https://orcid.org/0000-0002-1814-9773</orcidid><orcidid>https://orcid.org/0000-0001-5424-5714</orcidid><orcidid>https://orcid.org/0000-0001-7657-3065</orcidid><orcidid>https://orcid.org/0000-0002-8101-2497</orcidid><orcidid>https://orcid.org/0000-0002-1331-2906</orcidid><orcidid>https://orcid.org/0000-0002-7768-2455</orcidid></search><sort><creationdate>20210601</creationdate><title>Could the appropriate anti-diabetic therapy be mixed insulin in dialysis patients?</title><author>Demircan, Vehbi ; Yıldırım, Yaşar ; Aydın, Emre ; Kara, Ali Veysel ; Aydın, Fatma Yılmaz ; Yılmaz, Zülfükar ; Kadiroğlu, Ali Kemal ; Tuzcu, Alpaslan Kemal ; Pekkolay, Zafer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c270t-5267f83d99bbad6489e03c4676eb159115411b2bad9037d1ae0516d851178943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antidiabetics</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>End-stage renal disease</topic><topic>Family Medicine</topic><topic>General Practice</topic><topic>Health Administration</topic><topic>Hemodialysis</topic><topic>Hypoglycemia</topic><topic>Insulin</topic><topic>Kidney diseases</topic><topic>Medical treatment</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Morbidity</topic><topic>Nephrology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Renal failure</topic><topic>Sweating</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Demircan, Vehbi</creatorcontrib><creatorcontrib>Yıldırım, Yaşar</creatorcontrib><creatorcontrib>Aydın, Emre</creatorcontrib><creatorcontrib>Kara, Ali Veysel</creatorcontrib><creatorcontrib>Aydın, Fatma Yılmaz</creatorcontrib><creatorcontrib>Yılmaz, Zülfükar</creatorcontrib><creatorcontrib>Kadiroğlu, Ali Kemal</creatorcontrib><creatorcontrib>Tuzcu, Alpaslan Kemal</creatorcontrib><creatorcontrib>Pekkolay, Zafer</creatorcontrib><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>International journal of diabetes in developing countries</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Demircan, Vehbi</au><au>Yıldırım, Yaşar</au><au>Aydın, Emre</au><au>Kara, Ali Veysel</au><au>Aydın, Fatma Yılmaz</au><au>Yılmaz, Zülfükar</au><au>Kadiroğlu, Ali Kemal</au><au>Tuzcu, Alpaslan Kemal</au><au>Pekkolay, Zafer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Could the appropriate anti-diabetic therapy be mixed insulin in dialysis patients?</atitle><jtitle>International journal of diabetes in developing countries</jtitle><stitle>Int J Diabetes Dev Ctries</stitle><date>2021-06-01</date><risdate>2021</risdate><volume>41</volume><issue>2</issue><spage>288</spage><epage>292</epage><pages>288-292</pages><issn>0973-3930</issn><eissn>1998-3832</eissn><abstract>Background A good glycemic regulation should be provided to reduce mortality and morbidity in patients with end-stage renal failure due to diabetes mellitus. However, the use of insulin therapies in patients with renal failure is troublesome due to the increased rate of side effects. In our study, we investigated the frequency of hypoglycemia and its symptoms in patient groups receiving intensive and mixed insulin therapies. Materials and methods This prospective study included 89 hemodialysis patients with DM-related stage 5 chronic kidney disease who were followed up in a nephrology clinic of a university hospital between January 2013 and August 2015. Our study group was divided into two groups as those receiving intensive insulin therapy and mixed insulin therapy. Group 1 and group 2 consisted of 46 patients and 43 patients, respectively. Hypoglycemia (glucose &lt; 70 mg/dl) was investigated in patients with HbA1c levels that decreased below 7% after treatment, and the symptoms were evaluated according to the hypoglycemic scale. The results between the groups were evaluated using chi-square and Student’s t test Results A total of 89 patients were included in the study. HbA1c was 6.83% in the group receiving intensive insulin therapy and 6.95% in the group receiving mixed insulin therapy ( p &gt; 0.05). Hypoglycemia was detected in 27 patients (58.7%) in the intensive insulin therapy group and 14 patients (32.6%) in the mixed insulin therapy group. There was a significant level of hypoglycemia in the group receiving intensive insulin therapy ( p &lt; 0.05). In our study, the group receiving intensive insulin therapy had higher frequency and severity of common hypoglycemia symptoms such as confusion, sweating, weakness, dysphasia, palpitations, blurred vision, and feeling hungry. Conclusion There was a higher frequency of hypoglycemia under intensive insulin therapy in patients undergoing dialysis due to chronic kidney failure, which suggests that mixed insulin therapy is the ideal treatment to avoid hypoglycemia in this group of patients.</abstract><cop>New Delhi</cop><pub>Springer India</pub><doi>10.1007/s13410-020-00892-7</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-7251-046X</orcidid><orcidid>https://orcid.org/0000-0002-5323-2257</orcidid><orcidid>https://orcid.org/0000-0002-0378-8687</orcidid><orcidid>https://orcid.org/0000-0002-1814-9773</orcidid><orcidid>https://orcid.org/0000-0001-5424-5714</orcidid><orcidid>https://orcid.org/0000-0001-7657-3065</orcidid><orcidid>https://orcid.org/0000-0002-8101-2497</orcidid><orcidid>https://orcid.org/0000-0002-1331-2906</orcidid><orcidid>https://orcid.org/0000-0002-7768-2455</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0973-3930
ispartof International journal of diabetes in developing countries, 2021-06, Vol.41 (2), p.288-292
issn 0973-3930
1998-3832
language eng
recordid cdi_proquest_journals_2535300986
source Springer Nature - Complete Springer Journals
subjects Antidiabetics
Diabetes
Diabetes mellitus
End-stage renal disease
Family Medicine
General Practice
Health Administration
Hemodialysis
Hypoglycemia
Insulin
Kidney diseases
Medical treatment
Medicine
Medicine & Public Health
Morbidity
Nephrology
Original Article
Patients
Renal failure
Sweating
title Could the appropriate anti-diabetic therapy be mixed insulin in dialysis patients?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T17%3A10%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Could%20the%20appropriate%20anti-diabetic%20therapy%20be%20mixed%20insulin%20in%20dialysis%20patients?&rft.jtitle=International%20journal%20of%20diabetes%20in%20developing%20countries&rft.au=Demircan,%20Vehbi&rft.date=2021-06-01&rft.volume=41&rft.issue=2&rft.spage=288&rft.epage=292&rft.pages=288-292&rft.issn=0973-3930&rft.eissn=1998-3832&rft_id=info:doi/10.1007/s13410-020-00892-7&rft_dat=%3Cproquest_cross%3E2535300986%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2535300986&rft_id=info:pmid/&rfr_iscdi=true